Physician profile
Sarabjeet Singh
NPI 1295919371
$150,893.15
in general payments reported to CMS, 2019-2025
38 companies · $4,423 in 2025
The $4,423 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $25K · 2021: $13K · 2022: $18K · 2023: $3,565 · 2024: $17K · 2025: $4,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $4,907 · Travel and Lodging: $3,804 · Consulting Fee: $300 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,623.00 |
| Food and Beverage | $4,907.36 |
| Travel and Lodging | $3,804.39 |
| Consulting Fee | $300.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48,563.99 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $43,535.32 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27,270.16 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $16,811.93 | 2019-2024 | Lokelma |
| Pfizer INC. | $5,407.92 | 2019-2025 | |
| Abbott Laboratories | $2,555.93 | 2019-2025 | Cardiomems, Amplatzer Amulet, Jot Dx |
| Abiomed | $2,281.76 | 2019-2025 | Impella |
| Amgen INC. | $687.20 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $673.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $662.41 | 2021-2025 | Verquvo |
| Irhythm Technologies, INC. | $261.91 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Medtronic, INC. | $255.65 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Micra |
| Heartflow, INC. | $193.64 | 2025 | |
| Cardiovascular Systems INC. | $148.43 | 2020-2021 | |
| Medtronic Vascular, INC. | $146.58 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarabjeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.